Summit Therapeutics Inc. Increase Decrease In Cash And Cash Equivalents
Summit Therapeutics Inc. (SMMT) reported Increase Decrease In Cash And Cash Equivalents of -GBP 6.90 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2020-06-02
- Summit Therapeutics Inc. increase decrease in cash and cash equivalents for the quarter ending 2020-03-31 was -6.90M GBP, a 628.58% decline year-over-year.
- Summit Therapeutics Inc. increase decrease in cash and cash equivalents for the quarter ending 2019-10-31 was -6.38M GBP.
- Summit Therapeutics Inc. increase decrease in cash and cash equivalents for the quarter ending 2019-07-31 was -8.63M GBP.
- Summit Therapeutics Inc. increase decrease in cash and cash equivalents for the quarter ending 2019-04-30 was 1.30M GBP, a 81.80% decline year-over-year.
| Period end | Increase Decrease In Cash And Cash Equivalents 3 month | Increase Decrease In Cash And Cash Equivalents 6 month | Increase Decrease In Cash And Cash Equivalents 9 month | Increase Decrease In Cash And Cash Equivalents 11 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|---|---|---|
| 2020-03-31 | -6.90M GBP 6-K · filed 2020-06-02 | ||||
| 2019-12-31 | 21.77M GBP 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | -6.38M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -15.01M GBP derived: sum of 2 quarters · filed 2019-12-17 | -13.70M GBP 6-K · filed 2019-12-17 | ||
| 2019-07-31 | -8.63M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -7.32M GBP 6-K · filed 2019-10-11 | |||
| 2019-04-30 | 1.30M GBP 6-K · filed 2019-06-12 | ||||
| 2019-03-31 | 10.94M GBP 6-K · filed 2020-06-02 | ||||
| 2019-01-31 | 14.52M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 10.14M GBP derived: sum of 2 quarters · filed 2020-04-30 | -843.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 6.33M GBP 20-F · filed 2020-04-30 | |
| 2018-10-31 | -4.38M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -15.36M GBP derived: sum of 2 quarters · filed 2019-12-17 | -8.19M GBP 6-K · filed 2019-12-17 | -18.83M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-07-31 | -10.98M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -3.81M GBP 6-K · filed 2019-10-11 | -14.45M GBP derived: sum of 3 quarters · filed 2020-04-30 | -11.06M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-04-30 | 7.17M GBP 6-K · filed 2019-06-12 | -3.47M GBP derived: sum of 2 quarters · filed 2020-04-30 | -81.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 9.36M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-01-31 | -10.64M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -7.25M GBP derived: sum of 2 quarters · filed 2020-04-30 | 2.19M GBP derived: sum of 3 quarters · filed 2020-04-30 | -6.03M GBP 20-F · filed 2020-04-30 | |
| 2017-10-31 | 3.39M GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | 12.83M GBP derived: sum of 2 quarters · filed 2018-12-11 | 4.61M GBP 6-K · filed 2018-12-11 | ||
| 2017-07-31 | 9.45M GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 1.23M GBP 6-K · filed 2018-09-20 | |||
| 2017-04-30 | -8.22M GBP 6-K · filed 2018-06-05 | ||||
| 2017-01-31 | 12.47M GBP 20-F · filed 2019-03-29 | ||||
| 2016-01-31 | 4.92M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |